# MPCi

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/mpci
Canonical HTML page: https://gethealthbrief.com/entity/mpci

## Timeline

- **2026-08-10**: Series B financing closed — US$100 million Series B round closed, led by Granite Asia and a strategic investor, bringing total funding to nearly $200 million.
- **2023**: Company founded — Aureka Biotechnologies is founded as an AI-native TechBio company aiming to build biological world models.

## Recent coverage (1 stories)

### Aureka Biotech Lands $100M Series B to Build AI-Powered Biological World Model
2026-08-11 04:21:00 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Aureka Biotechnologies raised $100M to advance its foundational AI models that could transform drug discovery from a trial-and-error process into a predictive science. The funding will enhance a closed-loop system integrating AI models with high-throughput lab experiments, potentially slashing the time and cost of bringing new therapies to market.
Full story: https://gethealthbrief.com/story/aureka-biotech-100m-series-b-biological-world-model-healthcare

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.